Menu Search
Equities

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
900904:SHH

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.51
  • Today's Change-0.003 / -0.58%
  • Shares traded30.92k
  • 1 Year change-5.56%
  • Beta1.0507
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd is a China-based company primarily engaged in the research, development, production and sales of pharmaceuticals. The Company's products cover therapeutic areas such as anti-tumor, cold and cough, cardiovascular and cerebrovascular, rheumatic and bone pain, antifungal, tonic and tranquilizing, and gynecological. The Company’s main products include sodium cantharidinate and vitamin B6 injection, sodium cantharidinate injection, loquat cough granules, strong loquat dew, loquat cough capsules, Jinwu Gutong capsules, Shanhu Xuanjing, Jingwu capsules, Quantianma capsules, and Yindan Xintai dripping pills. The Company distributes its products within the domestic market and to overseas markets.

  • Revenue in CNY (TTM)1.88bn
  • Net income in CNY62.34m
  • Incorporated1992
  • Employees1.27k
  • Location
    Shanghai Shenqi Pharmaceutical Investment Management Co LtdRoom 613Changfa Tower, No. 128, Weihai RoadSHANGHAI 200003ChinaCHN
  • Phone+86 2 153750009
  • Fax+86 2 153750010
  • Websitehttp://www.gzsq.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.